Why Shares of Novavax, Inc. (NVAX) Are -2.79% Lower Today

Novavax, Inc. (NASDAQ:NVAX) is one of the worst performers on the stock market today. At current price of $7.57, the shares have already lost -0.22 points (-2.79% lower) from its previous close of $7.79. Should you buy or avoid them? The stock sets an active trading volume day with a reported 1323492 contracts so far this session. NVAX shares had a relatively better volume day versus average trading capacity of 3.99 million shares, but with a 31.92 million float and a 13.89% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for NVAX stock indicates that the average analyst price target is $13.75 per share. This means the stock has a potential increase of 81.64% from where the NVAX share price has been trading recently.

During the recent trading session for Novavax, Inc. (NASDAQ:NVAX), the company witnessed their stock rise $1.51 over a week and surge $3.04 from the price 20 days ago. When compared to their established 52-week high of $44.2, the high they recorded in their recent session happens to be higher. Their established 52-week high was attained by the company on 02/15/19. The recent low of $3.54 stood for a -82.94% since 11/21/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.88 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.

Looking at the current readings for Novavax, Inc., the two-week RSI stands at 58.66. This figure suggests that NVAX stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current NVAX readings is similarly very revealing as it has a stochastic reading of 55.33% at this stage. This figure means that NVAX share price today is being neutral.

Technical chart claims that Novavax, Inc. (NVAX) would settle between $8.06/share to $8.32/share level. However, if the stock price goes below the $7.52 mark, then the market for Novavax, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $7.24 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.5. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.

Analysts at B. Riley FBR, assumed coverage of NVAX assigning Buy rating, according to their opinion released on November 27. H.C. Wainwright analysts again handed out a Buy recommendation to Novavax, Inc. (NASDAQ:NVAX) stock but they lifted target price for the shares in a flash note issued to investors on August 14. The target price has been raised from $10 to $17. Analysts at Piper Jaffray lowered the stock to a Underweight call from its previous Overweight recommendation, in a research note that dated back to February 28.

NVAX equity has an average rating of 2.29, with the figure leaning towards a bullish end. 7 analysts who tracked the company were contacted by Reuters. Amongst them, 2 rated the stock as a hold while the remaining 5 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while others rated it as a sell. 4 analysts rated Novavax, Inc. (NASDAQ:NVAX) as a buy or a strong buy while 1 advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.

Novavax, Inc. (NVAX)’s current-quarter revenues are projected to climb by nearly -66.4% to hit $2.06 million, based on current consensus estimate. The firm’s full-year revenues are expected to expand by over -65.3% from $34.29 million to a noteworthy $11.9 million. At the other end of the current quarter income statement, Novavax, Inc. is expected to see its adjusted earnings surge by roughly 59.2% to hit $-1.06 per share. For the fiscal year, NVAX’s earnings are projected to climb by roughly 44.6% to hit $-5.54 per share.